Molecule in Python Blood Could Pave Way for New Obesity Drugs, Scientists Say
Scientists have isolated a gut‑bacterial metabolite, pTOS, that spikes in Burmese python blood after feeding and dramatically reduces appetite in obese mice. When administered to mice, pTOS caused a 9% body‑weight loss over 28 days without affecting energy expenditure. The molecule acts on the hypothalamus, a different pathway from GLP‑1 drugs like Wegovy, and is already present in low levels in human urine. Findings were published in Nature Metabolism, suggesting a novel avenue for obesity treatment.
Europe’s Last Chance to Revive Its Pharmaceutical Innovation Power
Europe’s pharmaceutical sector is losing its historic lead in R&D, with its share of global private research dropping from roughly half in 1990 to a third in 2025, while the United States now commands 55% and China is rapidly closing...
BioCina Launches Manufacturing Program for Patrys’ Injectable Delirium Therapy
BioCina has launched a comprehensive Chemistry, Manufacturing and Controls (CMC) program for Patrys Ltd’s injectable formulation RLS-2201, a proprietary quetiapine product aimed at treating acute delirium in intensive‑care patients. The manufacturing effort is based in BioCina’s sterile facility in Perth...
Metformin Reduces Weight Gain in Young People Taking Antipsychotics
A large pragmatic trial involving 1,565 overweight or obese youths with bipolar spectrum disorders found that adding metformin to a brief lifestyle program significantly blunted weight gain associated with second‑generation antipsychotics. Over six months, the metformin group’s BMI rose only...
FDA’s Draft Guidance on Alternatives to Animal Testing in Drug Development
The FDA issued draft guidance to help drug developers validate new approach methodologies (NAMs) as alternatives to animal testing. The guidance outlines four validation principles—context of use, human biological relevance, technical characterization, and fit‑for‑purpose—to ensure NAM data are reliable for...
After Buying HUB and Partnering with Promega, MilliporeSigma Charts Growth Path in Organoids
MilliporeSigma, the life‑science arm of Merck KGaA, completed its €104 million acquisition of HUB Organoids and has since integrated the business into its Discovery Solutions unit. The company launched a partnership with Promega to develop real‑time reporter assays for organoids, while...
STAT+: A Maryland Legislator Wants Pharma and Patient Groups to Disclose Ties to Disease Awareness Campaigns
A Maryland bill would force pharmaceutical companies and patient advocacy groups to disclose any financial ties when they run disease‑awareness advertisements. The legislation requires drugmakers to state whether they sell or are developing a treatment for the condition featured, and...
Boosting the Blood-Brain Barrier Could Avert Brain Damage in Athletes
Repeated head impacts in contact sports have been linked to lasting damage of the blood‑brain barrier (BBB), a finding that may underlie chronic traumatic encephalopathy (CTE). Researchers scanned 47 retired athletes using an MRI contrast agent that only enters brain...
FDA Seeks to Encourage Fewer Animal Studies with New Draft Guidance
The FDA released a draft guidance that details how biopharma firms can validate non‑animal approaches for early‑phase toxicology and safety studies. The document encourages the use of in‑vitro assays, computational modeling, and other modern methods to replace traditional animal testing....
HDX-MS Plus Computational Methods Provide Novel Approach to Study of Protein-Protein Interactions
Regeneron scientists have integrated hydrogen‑deuterium exchange mass spectrometry (HDX‑MS) with AI‑driven computational analysis to pinpoint binding sites, geometry, and stoichiometry in sandwich ELISA assays. The approach rapidly distinguishes protected versus exposed regions of antibodies, boosting assay specificity and sensitivity. By...
STAT+: Clearing Tumors in Mice, Azalea Therapeutics Advances Dream of in Vivo CAR-T Therapy
Azalea Therapeutics, a spinout from Jennifer Doudna’s lab, reported in Nature that its in vivo CAR‑T approach can generate functional CAR‑T cells directly within mice and eradicate both solid and hematologic tumors. The technique uses infused gene‑editing particles that precisely...
STAT+: A Huntington’s Researcher on the UniQure-FDA Fray
UniQure’s experimental gene‑therapy for Huntington’s disease, which previously reported a 75% slowdown in disease progression, has received a third consecutive rejection from the FDA. The trial’s lead investigator, Ed Wild of University College London, praised the early data but warned...
AI Startup Basecamp Research Announces Trillion-Gene Project
Basecamp Research, an AI‑focused biotech startup backed by Microsoft and Nvidia, announced a trillion‑gene sequencing initiative. The company aims to collect genetic sequences for over a trillion proteins within the next two years. Leveraging high‑performance cloud computing and advanced generative‑AI...
Ionis Delays Prion Disease Readout; Arvinas' Parkinson's Biomarker Data
Ionis Therapeutics announced that the primary completion date for its Phase 1/2a prion disease trial has been pushed to February 2027, extending the study timeline by more than two years. In parallel, Arvinas reported new biomarker data from its Parkinson’s disease program,...
Kennedy’s Vaccine Agenda Stalled, Structure’s ‘Competitive’ Obesity Pill, Novo’s Warning Letter
Structure Therapeutics reported a 16.3% weight loss after 44 weeks in a Phase 2 trial of its oral GLP‑1 pill, positioning it as a competitive alternative to Eli Lilly’s and Novo Nordisk’s candidates. Rhythm Pharmaceuticals disclosed that its obesity drug Imcivree failed in...
Briggs Morrison's Crossbow Unveils $77M Series B for T Cell Engagers
Crossbow Therapeutics, founded by biotech veteran Briggs Morrison, announced a $77 million Series B round to accelerate its off‑the‑shelf T‑cell engager platform. The funding, led by a mix of venture capital and strategic investors, will support the advancement of three preclinical candidates...
Aspen's Personalized Parkinson's Therapy Shows Early Promise
Aspen Neuroscience reported encouraging early data from a small autologous cell therapy trial for Parkinson's disease. The treatment, derived from each patient's own skin cells and reprogrammed into dopaminergic neurons, was safely implanted in twelve participants, showing graft survival and...
First MHRA/NICE Aligned Guidance Due in June
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) will begin delivering aligned guidance in June, enabling simultaneous licensing and reimbursement decisions for new medicines. Twenty‑seven companies have signed up...
Lilly-Backed China Startup Debuts With $68.7M Seed to Advance Next-Gen T Cell Engagers
Excalipoint Therapeutics, a Shanghai‑based biotech, closed a $68.7 million seed round, including a $41 million founding raise and a $27.7 million extension led by MPCi, Centurium Capital, Lilly Asia Ventures, and Eisai Innovation. The capital will fund six tri‑specific T‑cell engager candidates, notably...
STAT+: J&J Wins Approval for First-of-Its-Kind Psoriasis Pill
Johnson & Johnson received FDA clearance for Icotyde, the first oral daily pill for moderate‑to‑severe plaque psoriasis. The drug, originally called icotrokinra, is approved for patients aged 12 and older and is designed to replicate the efficacy of injectable biologics...
Myriad Genetics Receives the US FDA Approval for MyChoice CDx Test as a Companion Diagnostic for GSK’s Zejula
Myriad Genetics announced FDA approval of its MyChoice CDx test as a companion diagnostic for GSK’s Zejula (niraparib) in advanced ovarian cancer. The clearance follows the PRIMA trial, which showed that patients identified as HRD‑positive derived significant benefit from Zejula...
Navigating the Valley of Death: A How-To From an Investor’s Perspective
Biotech startups face the notorious "valley of death" as they move from proof‑of‑concept to commercialization, but investors remain active, with a 70.9% jump in venture‑financing deal value between Q2 and Q3 2025. A GlobalData survey shows 39% of respondents are...
Hope Rises for Vaccine Against Hookworm Parasite
A phase 2 trial of the Na‑GST1/Al–CpG vaccine demonstrated near‑complete protection against hookworm infection in healthy adults, with vaccinated participants shedding a median of zero eggs per gram versus 67 in the placebo group. The study, conducted in Washington, DC,...
Samsung Bioepis Partners with Sandoz for Up to Five Biosimilar Candidates
Samsung Bioepis and Sandoz have signed a global license, development and commercialization agreement covering up to five biosimilar candidates, including the preclinical SB36 biosimilar to Entyvio (vedolizumab). Samsung Bioepis will manage development, manufacturing and regulatory submissions, while Sandoz will handle...
US Court Says Pharma Giants Must Face False Claims Suit
The U.S. Ninth Circuit Court of Appeals denied dismissal motions by AbbVie, AstraZeneca, Novartis and Sanofi, allowing a whistleblower False Claims Act suit over alleged 340B program overcharges to proceed. The lawsuit, filed by Adventist Health System/West, claims the manufacturers...
Xaira Unveils AI Model X-Cell for Predicting Virtual Cells
Xaira, the biotech AI startup with the deepest funding round, launched its first model, X‑Cell, on Tuesday. The platform uses deep learning to generate virtual cell representations from multi‑omics data, enabling researchers to simulate cellular responses without physical experiments. Early...
R1 Therapeutics Raises $77.5m to Progress AP306 for Hyperphosphatemia
R1 Therapeutics announced a $77.5 million oversubscribed Series A round to advance AP306, a first‑in‑class pan phosphate transporter inhibitor for hyperphosphatemia in chronic kidney disease patients. The funding, led by Abingworth, F‑Prime and DaVita Venture Group, also secured an exclusive global licence...
Tick-Borne Encephalitis Study Identifies ABCG1 as Potential Target for Future Treatments
Researchers at the Medical University of Graz conducted one of the largest genome‑wide association studies on tick‑borne encephalitis (TBE), analyzing about 1,600 patients from multiple European nations. The study pinpointed variants in the cholesterol‑transport gene ABCG1 as a genetic risk...
START and Trialing Collaborate on Oncology Clinical Trials
START Center for Cancer Research has partnered with Trialing to broaden access to early‑phase oncology clinical trials throughout Europe. The exclusive agreement lets START distribute curated trial information and real‑time enrollment updates via Trialing’s platform, directly notifying oncologists when slots...
Promising Biotechs in Maryland Right Now
Maryland’s life‑science cluster, home to over 2,700 institutions, is projected to generate a $16.7 billion R&D market by 2026. Six home‑grown biotech firms—SciNeuro, Gain Therapeutics, Theriva Biologics, Supernus Pharmaceuticals, Elixirgen Therapeutics and Altimmune—have secured sizable financing and strategic partnerships in the...
Co PSMA Prostate Imaging Data Presented at EAU Congress
Clarity Pharmaceuticals presented Phase II Co‑PSMA data at the EAU Congress, showing its 64Cu‑SAR‑bisPSMA PET tracer outperforms the standard 68Ga‑PSMA‑11 in detecting prostate cancer recurrence at low PSA levels. In 50 men post‑radical prostatectomy, 64Cu‑SAR‑bisPSMA identified 63 lesions versus 24...
Cogent Biosciences Reports US FDA’s NDA Acceptance of Bezuclastinib for NonAdvanced Systemic Mastocytosis (NonAdvSM)
Cogent Biosciences announced that the U.S. FDA has accepted its new‑drug application for bezuclastinib in non‑advanced systemic mastocytosis (NonAdvSM), with a PDUFA target date of December 30 2026 and no advisory committee required. The filing is supported by the SUMMIT trial, which...
Ascendis Pharma Reports Topline P-II (New InsiGHTS) Trial Data on TransCon hGH in Turner Syndrome
Ascendis Pharma released topline results from its Phase‑II New InsiGHTS trial evaluating TransCon hGH (lonapegsomatropin) administered once‑weekly versus daily somatropin in 49 prepubertal children with Turner syndrome. At week 52, the weekly formulation achieved an LS mean annualized height velocity...
Voro Therapeutics Collaborates with Daiichi Sankyo to Develop Tumor-Activated ADCs
Voro Therapeutics has signed a research collaboration with Daiichi Sankyo’s San Diego research institute to create tumor‑activated antibody‑drug conjugates (ADCs) using Voro’s PrimeBody platform. The partnership will focus on masked ADCs that employ proprietary masking domains and protease‑cleavable linkers to achieve...
Chinese Scientists Use E Coli to Fight Breast Tumours From Within in Mice Study
Chinese researchers at Shandong University have engineered the probiotic strain Escherichia coli Nissle 1917 to synthesize and deliver the anticancer drug Romidepsin directly within breast‑tumor tissue in mice. The bacteria colonized the tumors, releasing the drug locally and achieving tumor‑inhibiting...
How TrumpRx Drug Prices Compare With Those in Other Countries
President Trump’s TrumpRx website claims to offer the world’s lowest prescription‑drug prices, but a New York Times analysis finds the opposite. The site lists only a few dozen negotiated U.S. prices, omitting widely used drugs such as statins and many high‑cost cancer...
Prodrug-Tethered Lipid Nanoparticles for Synergistic Messenger RNA Cancer Immunotherapy
Researchers have engineered lipid nanoparticles tethered with a prodrug that releases an IDO‑1 inhibitor while simultaneously delivering mRNA encoding interleukin‑12. The dual‑action formulation, administered intratumorally, generated robust CD8⁺ T‑cell responses, mitigated T‑cell exhaustion, and produced complete tumor regressions in several...
FTC Monitoring How Drug Companies React to Patent Cliff, Official Says
The U.S. Federal Trade Commission announced it is closely monitoring how pharmaceutical companies respond to the upcoming patent cliff affecting numerous blockbuster drugs. FTC antitrust director Dan Guarnera said the agency’s “laser focus” on healthcare will target any anticompetitive conduct...
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
Zymeworks will present Phase 1 data on its folate‑receptor‑alpha ADC ZW191 and preclinical results for a novel pan‑RAS inhibitor ADC platform at the AACR Annual Meeting. The oral presentation will detail dose‑escalation safety and efficacy in advanced solid tumours, while...
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
ORIC Pharmaceuticals announced that two preclinical abstracts on its PRC2‑targeting agent rinzimetostat (ORIC‑944) have been accepted for poster presentation at the 2026 AACR Annual Meeting. The data show rinzimetostat, an allosteric EED inhibitor, maintains potency against EZH1‑overexpressing complexes and key...
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel Dual-Target MUC16/NaPi2b Tetravalent ADC ARR-002...
ArriVent BioPharma will showcase two preclinical posters at the 2026 AACR Annual Meeting, highlighting its EGFR inhibitor firmonertinib and the dual‑target tetravalent ADC ARR-002. Firmonertinib demonstrates high‑potency inhibition of both classical EGFR mutations and exon‑20 insertion variants, with strong brain...
Study Finds GLP-1 Drugs Can Help Curb SUDs
A BMJ study of more than 600,000 Veterans Affairs patients with type‑2 diabetes found that glucagon‑like peptide‑1 (GLP‑1) drugs significantly lowered the risk of developing substance‑use disorders, including alcohol, cannabis, nicotine, cocaine and opioids. The analysis compared GLP‑1 therapy with...
Clinical Trial Results Support Use of Weekly Extended-Release Buprenorphine for Treatment of Opioid Use Disorder During Pregnancy
A NIH‑backed multicenter trial of 140 pregnant adults found that weekly injectable extended‑release buprenorphine achieved significantly higher rates of illicit opioid abstinence than daily sublingual buprenorphine, while also reducing serious maternal adverse events. The study, published in JAMA Internal Medicine,...
ABIONYX Pharma: Availability of the Universal Registration Document for the Year 2025
ABIONYX Pharma filed its Universal Registration Document (URD) for the fiscal year 2025 with the French regulator AMF on March 17, 2026 (filing D. 26‑0099). The URD is now publicly available on both the company’s website and the AMF portal. The...
Transient but Transformative: Sanofi’s mRNA CAR-T Enters in Vivo Race
Sanofi unveiled pre‑clinical data for an in‑vivo CAR‑T platform that delivers mRNA via lipid nanoparticles (LNPs) and a CD8‑targeting VHH nanobody, eliminating the weeks‑long ex‑vivo manufacturing step. The approach achieved tumor suppression in mice with less than 5% liver uptake...
Bicycle to Lay Off 30% of Staff, Pivot Away From Padcev Challenger
Biotech firm Bicycle Therapeutics announced it will lay off roughly 30% of its workforce, about 86 employees, as it deprioritizes its experimental ADC zelenectide‑pevedotin. Regulators expressed doubts that the Phase 2 Duravelo‑2 trial data will support accelerated approval for metastatic bladder...
Autologous versus Allogeneic: How Cell Therapy Development Is Changing in Oncology
Autologous CAR‑T therapies dominate the current market but face logistical and clinical challenges. Patients must undergo leukapheresis, endure long vein‑to‑vein times, and often need bridging therapy, which can cause adverse events. To address these issues, companies are shifting toward off‑the‑shelf...
FDA Warns Telehealth Companies Over Marketing of Compounded GLP-1 Weight-Loss Drugs
On February 20, 2026, the FDA issued warning letters to 30 telehealth companies for misleading claims about compounded GLP‑1 weight‑loss drugs such as semaglutide and tirzepatide. The agency highlighted that compounded products are not FDA‑reviewed for safety, efficacy, or quality,...
NQO1‐Responsive Prodrug for in Cellulo Release of Cytochalasin B as Cancer Cell‐Targeted Migrastatic (Small 16/2026)
Researchers introduced BQTML‑CB, an NQO1‑responsive prodrug that releases cytochalasin B inside tumor cells, disrupting actin filaments and halting migration and proliferation. The design exploits the enzyme NQO1, overexpressed in many aggressive cancers, to achieve tumor‑selective activation while sparing NQO1‑deficient cells and...
Bioengineered Bacterial Vesicles and Biomimetic Hybrids Eliminate Biofilms and Balance the Gut Microbiome
Researchers have engineered biomimetic nanocarriers that combine liposomal structures with Myxobacteria outer‑membrane vesicles (OMVs) to deliver antibiotics. The hybrid carriers achieve higher drug loading and can penetrate intracellular Gram‑negative pathogens, while native OMVs avoid immune clearance and sustain extracellular exposure....